| Literature DB >> 24374050 |
Mara Soledad Trebucobich1, María Herminia Hazelhoff1, Alberto A Chevalier2, Sabina Passamonti3, Anabel Brandoni1, Adriana Mónica Torres4.
Abstract
Bilitranslocase (BTL) is a plasma membrane carrier that transports organic anions of physiological and pharmacological interest. It is expressed in basolateral plasma membrane of kidney and liver. BTL has been recently described as a marker of transition from normal tissue to its neoplastic transformation in human kidney. Inorganic mercury is a major environmental contaminant that produces many toxic effects. Previous reports have described an interaction between BTL and mercuric ions. This study was designed to evaluate the renal and hepatic expression of BTL in rats exposed to a nephrotoxic and hepatotoxic dose of HgCl2. Male rats were treated with a single injection of HgCl2 at a dose of 4mg/kg body wt, i.p. (HgCl2 group). Control rats received the vehicle alone (Control group). Studies were carried out 18h after injection. Afterwards, the kidneys and livers were excised and processed for histopathological studies or immunoblot (homogenates and crude membranes) techniques. In rats treated with HgCl2, immunoblotting showed a significant decrease in the abundance of BTL in homogenates and plasma membranes from kidney and liver. BTL decrease of expression might reflect the grade of damage in renal tubule cells and in hepatocytes. Thus, BTL might be postulated as a new biomarker of tissue toxicity induced by mercury.Entities:
Keywords: Bilitranslocase; Hepatotoxicity; Mercuric chloride; Nephrotoxicity; Tissue biomarker
Mesh:
Substances:
Year: 2013 PMID: 24374050 DOI: 10.1016/j.toxlet.2013.11.022
Source DB: PubMed Journal: Toxicol Lett ISSN: 0378-4274 Impact factor: 4.372